Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Recruiting

Study on Customized Antibiotic Treatment Duration for Hospitalized Patients with Community-Acquired Pneumonia Using Cefotaxime and Drug Combination

Verified siteRegistered drugNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial focuses on patients with community-acquired pneumonia, a type of lung infection that is acquired outside of a hospital setting. The study aims to evaluate a new approach to antibiotic treatment duration, comparing it to the standard treatment duration. The antibiotics being studied include amoxicillin, amoxicillin and beta-lactamase inhibitor, pristinamycin, levofloxacin, ceftriaxone, and cefotaxime. These medications are commonly used to treat bacterial infections and will be administered either orally or through injections.

Participants in the study will receive one of the antibiotics mentioned above, or a placebo, for a period of up to 10 days. The study will monitor patients to determine when it is safe to stop the antibiotic treatment based on specific health criteria, such as body temperature and heart rate. The goal is to see if stopping antibiotics when these criteria are met is as effective as the traditional longer treatment duration.

The trial will track the patients' recovery over a period of 30 days, checking for the persistence of stability criteria, the need for additional antibiotic treatment, and overall health outcomes. The study will also assess the impact of the treatment on the patients' quality of life and any side effects experienced during the trial period. This research aims to improve the management of community-acquired pneumonia by potentially reducing the duration of antibiotic use without compromising patient recovery.

The research process

The trial runs in 6 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Upon joining the study, you will be informed about the trial's purpose and procedures. You will be asked to provide informed consent, confirming your understanding and willingness to participate.

  2. Step 2

    Initial assessment

    An initial assessment will be conducted to confirm eligibility. This includes checking for symptoms of community-acquired pneumonia and ensuring you meet the study's inclusion criteria.

  3. Step 3

    Treatment phase

    You will receive antibiotic treatment for a minimum of 48 hours. The specific medication and dosage will be determined based on your condition and may include options such as amoxicillin, pristinamycin, cefotaxime, levofloxacin, or ceftriaxone.

    The route of administration will vary: some medications are taken orally, while others may be given through an injection or infusion.

  4. Step 4

    Monitoring stability

    Your health will be monitored to assess stability. Stability is defined by criteria such as normal body temperature, heart rate, blood pressure, and oxygen levels.

    If stability is achieved after at least 48 hours of treatment, the duration of antibiotic use may be adjusted.

  5. Step 5

    Follow-up assessments

    Follow-up assessments will occur at various intervals, including Day 15 and Day 30 after treatment initiation. These assessments will evaluate the rate of cure and monitor any symptoms or side effects.

    Your quality of life and any changes in pneumonia symptoms will also be assessed during these follow-ups.

  6. Step 6

    Completion of the study

    Upon completion of the study, a final evaluation will be conducted to ensure all criteria have been met and to document any outcomes or adverse events.

    The study aims to determine the effectiveness of customized antibiotic treatment duration for patients with moderately severe community-acquired pneumonia.

Who can join the trial?

19 criteria

  • Must be an adult (18 years or older).
  • Must have a negative viral respiratory test. If the test is positive, there must be proof of a bacterial infection.
  • Must be expected to need antibiotics for at least one more day if not in the experimental group.
  • Must be hospitalized for suspected community-acquired pneumonia, shown by at least two of these symptoms:
    • Fever (temperature over 38°C) or low body temperature (below 36°C)
    • Shortness of breath (dyspnea)
    • Cough
    • Producing thick mucus (purulent sputum)
    • Crackling sounds in the lungs
    • Must have new lung changes visible on a chest X-ray or CT scan.
    • Must have been treated with antibiotics for at least 48 hours and no more than 7 days, following French guidelines, and still be on antibiotics.
    • Must show signs of clinical improvement in the last 24 hours, including:
      • Normal body temperature (≤ 37.8°C)
      • Heart rate under 100 beats per minute
      • Breathing rate under 24 breaths per minute
      • Oxygen levels in the blood at or above 92%
      • Blood pressure at or above 90 mmHg
      • No other infections besides the respiratory one.
      • Must have health insurance or government medical aid.
      • Must have given informed consent to participate.
      • Must understand oral and written French, or have a relative who can help with communication and study documents.

Who cannot join the trial?

8 criteria

  • Patients who have a different type of infection other than community-acquired pneumonia cannot participate. Community-acquired pneumonia is a lung infection that you get outside of a hospital setting.
  • Patients who are under 18 years old or over 65 years old are not eligible to join the study.
  • Patients who are pregnant or breastfeeding cannot take part in the study.
  • Patients who have a weakened immune system, which means their body has a harder time fighting infections, are not allowed to participate.
  • Patients who are currently participating in another clinical trial are not eligible.
  • Patients who have a history of severe allergic reactions to antibiotics cannot join the study.
  • Patients with severe liver or kidney disease are not allowed to participate.
  • Patients who have a mental health condition that makes it difficult to understand or follow the study instructions cannot take part.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Experimental Strategy on Antibiotic Treatment: This is a new approach being tested in the trial. It involves giving antibiotics to patients with community-acquired pneumonia and stopping the treatment when the patient shows signs of stability, but only after they have been on the medication for at least 48 hours. The goal is to see if this method is as effective as the usual practice of giving antibiotics for a set number of days. This strategy is being tested to potentially reduce the duration of antibiotic use while still effectively treating the infection.

What is already known about the treatment

Experimental Antibiotic Strategy – This medication is administered to patients in a hospital setting, typically through oral or intravenous routes, depending on the patient's condition. It is currently being studied in clinical trials to determine its effectiveness in treating community-acquired pneumonia by adjusting the duration of antibiotic treatment based on patient stability. The main therapeutic indication is for moderately severe community-acquired pneumonia. The medication works by targeting and inhibiting the growth of bacteria responsible for the infection, allowing the body's immune system to clear the infection more effectively. It falls under the pharmacological classification of antibiotics, which are drugs used to treat bacterial infections.

Investigated diseases

Community-acquired pneumonia – Community-acquired pneumonia is an infection of the lungs that occurs in individuals who have not recently been hospitalized. It is typically caused by bacteria, viruses, or fungi that are inhaled into the lungs. The disease begins with symptoms such as cough, fever, chills, and difficulty breathing. As it progresses, patients may experience chest pain, fatigue, and confusion, especially in older adults. The infection leads to inflammation and fluid accumulation in the air sacs of the lungs, impairing oxygen exchange. Recovery involves the resolution of symptoms and the clearing of the infection from the lungs.
Trial detailsLast updated 7 Oct 2026
Age18+ yearsPhasePhase IIITrial ID2023-504208-27-00Protocol codeAPHP220814Estimated enrolment424 patientsSponsorAssistance Publique Hopitaux De Paris

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.